贝伐珠单抗联合白蛋白结合型紫杉醇治疗复发难治肺腺癌的疗效研究  

Efficacy of bevacizumab combined with albumin-bound paclitaxel in the treatment of recurrent and refractory lung adenocarcinoma

作　　者：王玥玥 WANG Yue-yue(Department of Radiotherapy,Dandong First Hospital,Dandong 118000,China)

机构地区：[1]丹东市第一医院放疗科,118000

出　　处：《中国现代药物应用》2021年第14期124-126,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探讨贝伐珠单抗联合白蛋白结合型紫杉醇治疗复发难治肺腺癌的疗效。方法74例复发难治肺腺癌患者,按治疗方法不同将其分为研究组与对照组,每组37例。对照组仅采取最佳支持治疗,研究组采取贝伐珠单抗联合白蛋白结合型紫杉醇治疗。比较两组血清糖类抗原(CA125)、癌胚抗原(CEA)水平及临床疗效、体重变化、生活质量评分。结果研究组血清CA125、CEA水平分别为(29.53±3.42)U/ml、(10.92±2.13)ng/ml,均低于对照组的(35.16±3.07)U/ml、(17.04±4.83)ng/ml,差异有统计学意义(P<0.05)。研究组有效率40.5%、临床获益率83.8%均高于对照组的8.1%、56.8%,差异有统计学意义(P<0.05)。研究组体重情况优于对照组,生活质量评分(91.66±11.05)分高于对照组的(83.17±15.36)分,差异均有统计学意义(P<0.05)。结论复发难治肺腺癌患者采用贝伐珠单抗联合白蛋白结合型紫杉醇治疗可显著降低血清CA125、CEA水平,维持体重,有效提高临床疗效及生活质量。Objective To investigate the efficacy of bevacizumab combined with albumin-bound paclitaxel in the treatment of recurrent and refractory lung adenocarcinoma.Methods 74 patients with recurrent and refractory lung adenocarcinoma were divided into a study group and a control group according to their treatment method,with 37 patients in each group.The control group only received the best supportive treatment,while the study group received bevacizumab combined with albumin-bound paclitaxel.The levels of carbohydrate antigen(CA125),carcinoembryonic antigen(CEA)in serum,clinical efficacy,body weight and life quality were compared between these two groups.Results The levels of CA125 and CEA in serum in the study group were(29.53±3.42)U/ml,(10.92±2.13)ng/ml,which were lower than(35.16±3.07)U/ml,(17.04±4.83)ng/ml in the control group,and the difference was statistically significant(P<0.05).The study group had an effective rate of 40.5%and a clinical benefit rate of 83.8%,which were higher than 8.1%and 56.8%of the control group,the difference was statistically significant(P<0.05).The body weight condition of the study group was better than that of the control group,and the score of life quality of the study group was(91.66±11.05)points,which was higher than(83.17±15.36)points of the control group,the difference was statistically significant(P<0.05).Conclusion Bevacizumab combined with albumin-bound paclitaxel can significantly reduce levels of CA125 and CEA in serum,maintain body weight,improve clinical efficacy and life quality in patients with recurrent and refractory lung adenocarcinoma.

关 键 词：贝伐珠单抗 白蛋白结合型紫杉醇 肺腺癌 复发 

分 类 号：R734.2[医药卫生—肿瘤]